Provided by Tiger Trade Technology Pte. Ltd.

Rezolute, Inc.

4.06
-0.3400-7.73%
Pre-market: 4.210.1500+3.69%05:45 EDT
Volume:2.07M
Turnover:8.53M
Market Cap:390.95M
PE:-5.05
High:4.55
Open:4.55
Low:4.02
Close:4.40
52wk High:11.46
52wk Low:1.07
Shares:96.29M
Float Shares:72.51M
Volume Ratio:2.45
T/O Rate:2.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8039
EPS(LYR):-0.9791
ROE:-81.73%
ROA:-48.74%
PB:3.35
PE(LYR):-4.15

Loading ...

Rezolute Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Rezolute Q3 net loss narrows as R&D expenses fall

Reuters
·
May 13

Rezolute Q3 FY26 net loss narrows to $16.2 million

Reuters
·
May 13

BRIEF-Rezolute Q3 EPS USD -0.16

Reuters
·
May 13

Press Release: Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

Dow Jones
·
May 13

Rezolute management attends H.C. Wainwright BioConnect investor conference

Reuters
·
May 11

Rezolute Inc expected to post a loss of 18 cents a share - Earnings Preview

Reuters
·
May 09

Rezolute publishes corporate presentation on ersodetug treatment for hyperinsulinism hypoglycemia

Reuters
·
May 02

Rezolute presents results from Phase 3 sunRIZE study of ersodetug at PES 2026

TIPRANKS
·
May 02

Rezolute reports Phase 3 sunRIZE CGM data showing improved hypoglycemia control with ersodetug

Reuters
·
May 02

Rezolute Announces Oral Presentation of Results From Its Phase 3 Sunrize Study of Ersodetug in Patients With Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting

THOMSON REUTERS
·
May 02

Rezolute to present Phase 3 sunRIZE ersodetug data in congenital hyperinsulinism at PES meeting

Reuters
·
Apr 21

Rezolute publishes corporate presentation on ersodetug Phase 3 hyperinsulinism programs

Reuters
·
Apr 01

Rezolute CFO Daron Evans reports purchase of common shares worth $28,500

Reuters
·
Apr 01

Analysts Offer Insights on Healthcare Companies: Sight Sciences (SGHT), Atara Biotherapeutics (ATRA) and Rezolute (RZLT)

TIPRANKS
·
Mar 30

Rezolute Raised to Outperform From Neutral by Wedbush

Dow Jones
·
Mar 25

Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Rezolute (RZLT) and Demant (OtherWILLF)

TIPRANKS
·
Mar 25

Rezolute upgraded to Outperform from Neutral at Wedbush

TIPRANKS
·
Mar 25

H.C. Wainwright Sticks to Their Buy Rating for Rezolute (RZLT)

TIPRANKS
·
Mar 25

Wedbush Upgrades Rezolute to Outperform From Neutral, Raises Price Target to $5 From $2

MT Newswires Live
·
Mar 25